Summary: Transcranial Magnetic Stimulation (TMS) has been a lifeline for patients with treatment-resistant depression, but its internal mechanics remained a “black box” until now. Researchers revealed that an accelerated form of TMS (aiTBS) physically repairs brain circuits damaged by chronic stress.
By using a first-of-its-kind preclinical model, the team watched as lost synaptic structures “re-emerged” within just 24 hours. The study identifies a specific class of neurons, IT neurons, as the primary targets of this magnetic “reawakening,” providing a structural explanation for why the therapy’s effects are both rapid and long-lasting.
Key Facts
- The Structural Scaffolding: Chronic stress causes neurons in the prefrontal cortex to lose dendritic spines, tiny protrusions that act as the physical landing pads for communication between brain cells.
- Cellular Precision: While researchers expected a broad effect, TMS was “surprisingly precise.” It selectively restored the dendritic spines and activity of Intratelencephalic (IT) neurons, while leaving neighboring neuron types largely unchanged.
- Accelerated Healing (aiTBS): While standard TMS takes weeks, the accelerated protocol (aiTBS) compresses treatment into five days. The UCLA study showed significant structural repair and behavioral improvement in mice after just one day of stimulation.
- Essential Circuitry: When researchers blocked IT neuron activity, the antidepressant effects of the TMS vanished, proving these specific cells are the “engine” behind the recovery.
- Persistence: The physical changes to the neurons were stable, allowing therapeutic benefits to persist for at least a week after a single day of treatment, suggesting TMS doesn’t just “boost” activity, it restores structure.
Source: UCLA
Transcranial magnetic stimulation (TMS) is a non-invasive, FDA-approved therapy that uses brief magnetic pulses to treat depression, particularly in patients who do not respond to medication. Yet scientists have long struggled to understand how it works at the level of brain cells and circuits.
Now, researchers at UCLA Health have opened that black box.
In a study published in Cell, a collaborative team out of the UCLA Neuromodulation Division reported the first preclinical model showing how a fast-acting form of TMS physically repairs brain circuits disrupted by stress to produce antidepressant effects. Remarkably, TMS selectively targeted specific brain cells to restore a disrupted communication channel in the brains of mice.
The findings could lead to brain stimulation therapies that are more effective, precise and longer lasting, not only for depression, but potentially for a wide range of neurological and psychiatric disorders.
The study was co-led by Dr. Scott Wilke, assistant professor of psychiatry and the Penske Family Chair in Neuromodulation at UCLA Health, and Dr. Laura DeNardo, associate professor of physiology in the David Geffen School of Medicine at UCLA
“This work brings together what we see in the clinic with the kind of cellular-level insight you can only get from advanced neuroscience tools”, said Wilke, who is also a psychiatrist with the UCLA TMS Clinical and Research Service.
“For the first time, we can see exactly which brain cells are changed by this rapid treatment and how that restoration supports recovery of depression-related behaviors.
In repetitive transcranial magnetic stimulation (rTMS), pulsed electromagnetic fields are delivered through a coil placed on the scalp to focally stimulate brain activity. While effective, standard rTMS protocols typically require daily treatments over 6 weeks or longer.
In recent years, clinicians have developed accelerated intermittent theta burst stimulation (aiTBS), which compresses treatment into just five days and can produce rapid relief of depressive symptoms. Despite growing clinical use, the biological basis of these fast and long-lasting effects remained largely unknown.
To investigate this, the UCLA team collaborated with scientists at the National Institutes of Health to invent a novel method that enables them to stimulate the mouse brain in a way that is similar to how patients are treated in the clinic. Using mice exposed to chronic stress to simulate depression, the researchers were able to stimulate awake animals while monitoring brain activity in real time.
The researchers discovered that chronic stress caused neurons in the prefrontal cortex to lose dendritic spines, which are tiny protrusions that support synaptic communication between brain cells. This loss of synaptic structures was observed across multiple neuron types.
They found just one day of aiTBS restored these lost connections and led to enhanced activity during depression-related behaviors but only in a specific class of neurons known as intratelencephalic (IT) neurons. Other neighboring neuron types were largely unaffected.
“We initially thought TMS might broadly affect the prefrontal cortex, but instead the effects were surprisingly precise,” said Michael Gongwer, the study’s first author and an MD-PhD student at UCLA Health. “Seeing lost synaptic structures re-emerge and then seeing those same neurons regain activity during behavior was incredibly exciting”
When the researchers selectively blocked IT neuron activity during stimulation, the antidepressant effects disappeared, demonstrating that these neurons are essential for the therapy’s behavioral benefits.
“Stress disrupts the structural scaffolding neurons rely on to communicate,” said DeNardo. “By restoring those structures in IT neurons, the stimulation re-engages circuits that support adaptive behavior.”
The researchers observed rapid improvements in stress-related behaviors within 24 hours of treatment. Importantly, these therapeutic effects on behavior persisted for at least one week after only a single day of stimulation and were accompanied by stable structural changes in IT neurons.
“What’s striking is that this isn’t just a temporary shift in activity,” Wilke said. “The treatment restores neuronal structure in a way that allows normal circuit function and behavior to recover.”
While animal models cannot fully capture the complexity of human depression, the study provides some of the strongest evidence to date for how brain stimulation can rapidly produce therapeutic effects at the cellular and circuit level.
Beyond depression, TMS is being used for disorders including chronic pain, OCD, PTSD, and tinnitus, which are all conditions which arise from dysfunction in specific brain circuits. This research points towards opportunities to make neuromodulation treatments even more effective.
“Every patient is unique,” Wilke said. “By studying these treatments in mice, we can systematically test how different stimulation parameters reshape brain circuits, which may ultimately help us tailor neuromodulation therapies to individual patients.”
Key Questions Answered:
A: Currently, TMS is primarily FDA-approved for treatment-resistant depression (where meds have failed). However, as we move from 6-week protocols to these 5-day accelerated versions, and as we understand the cellular “precision” shown in this study, it may become a much more common early-stage option.
A: Yes. TMS is already being used for those conditions. Because PTSD and OCD also involve “broken” communication channels in specific brain circuits, the ability of TMS to restore dendritic spines in targeted neurons could be the key to long-term relief across multiple psychiatric disorders.
A: The study showed that the structural changes were stable for at least a week after a single day of treatment. In humans, clinical success often lasts months or years, but some patients require “maintenance” sessions to keep those synaptic bridges strong against future stress.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this TMS and depression research news
Author: Will Houston
Source: UCLA
Contact: Will Houston – UCLA
Image: The image is credited to Neuroscience News
Original Research: The findings will appear in Cell
